



Claims

1. A compound as shown in formula (I), a tautomer, a stereoisomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof:



wherein, n and m are each independently 0, 1, 2, or 3;

Cy^A is selected from the group consisting of:



wherein denotes a bond connected to Cy^B, and denotes a bond connected to Cy^C;

Cy^B is selected from the group consisting of: C₆₋₁₀ aryl and 5-12 membered heteroaryl;

Cy^C is selected from the group consisting of: C₆₋₁₀ aryl, 5-12-membered heteroaryl, saturated or partially unsaturated C₃₋₆ carbocyclyl and saturated or partially unsaturated 4-12-membered heterocyclyl;

R₁ is selected from the group consisting of: H, D, halogen, CN, OH, NH₂, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₁₋₆ alkylamino, C₂₋₄ alkenyl, C₁₋₄ haloalkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkynyl, C₃₋₆ saturated or partially unsaturated carbocyclyl, C₃₋₆ halogenated saturated or partially unsaturated carbocyclyl, C₃₋₆ saturated or partially unsaturated carbocyclyl-O-, SF₅ and 4-12 membered heterocyclyl;


R₂ and R₃ are each independently selected from the group consisting of: C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₁₋₆ alkylamino, C₃₋₆ saturated or partially unsaturated carbocyclyl and 4-12-membered heterocyclyl; wherein R₂ and R₃ can be the same or different; or R₂ and R₃ together with the sulfur atom to which they are connected form a 4-12-membered heterocyclyl;

R₄ is selected from the group consisting of: H, D, halogen, CN, OH, NH₂, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₁₋₆ alkylamino, C₂₋₄ alkenyl, C₁₋₄ haloalkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkynyl, C₃₋₆ saturated or partially unsaturated carbocyclyl, C₃₋₆ halogenated

saturated or partially unsaturated carbocyclyl, C₃₋₆ carbocyclyl-O-, SF₅ and 4-12-membered heterocyclyl;

R₅ is -L-R_w, wherein L is selected from the group consisting of: covalent bond, -C₁₋₄ alkyl-, -NR₆-, -C₁₋₄ alkyl NR₆-;

5 R₆ is selected from the group consisting of: H, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl and C₁₋₆ haloalkoxy;



10 12-membered nitrogen-containing heterocyclyl;

R^{WA}, R^{WB}, and R^{WC} are each independently selected from the group consisting of: H, D, halogen, CN, C(O)Ra, C(O)ORa, NRaRb, C(O)NRaRb, C(O)NRaORb, or selected from the group consisting of: C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, phenyl, 3 to 7-membered saturated or partially unsaturated heterocyclyl with 1 to 2 heteroatoms independently
15 selected from nitrogen, oxygen and sulfur, and 5 to 6-membered heteroaryl with 1 to 4 heteroatoms independently selected from nitrogen, oxygen and sulfur; and the R^{WA}, R^{WB}, and R^{WC} can each be independently substituted with 1, 2, or 3 substituents selected from the group consisting of: C₁₋₆ alkylamino and C₁₋₆ alkoxy;

or R₆ and R_w together form a ring; and the ring is selected from the group consisting of: 5-
20 12 membered heteroaryl and 4-12 membered heterocyclyl;

R₇ is selected from the group consisting of: H, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₁₋₆ alkylamino, C₂₋₄ alkenyl, C₁₋₄ haloalkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkynyl, C₃₋₆ saturated or partially unsaturated carbocyclyl, C₃₋₆ halogenated saturated or partially unsaturated carbocyclyl, C₆₋₁₀ aryl, 5-12 membered heteroaryl, 4-12-membered heterocyclyl; or R₄ and R₇, as
25 well as the atoms between them, together form a ring, and the ring is selected from the group consisting of: C₆₋₈ saturated or partially unsaturated carbocyclyl, C₆₋₁₀ aryl, 6-12 membered heteroaryl and 6-12 membered saturated or partially unsaturated heterocyclyl;

R₈ is selected from the group consisting of: H, OH, NH₂, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy and C₁₋₆ alkylamino;

30 R₉ is selected from the group consisting of: H, D, halogen, CN, NH₂, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy and C₁₋₆ alkylamino;


unless otherwise specified, each of the above-mentioned alkyl, alkoxy, haloalkyl, haloalkoxy, alkylamino, alkenyl, haloalkenyl, alkynyl, haloalkynyl, saturated or partially

unsaturated carbocyclyl, halogenated saturated or partially unsaturated carbocyclyl, saturated or partially unsaturated heterocyclyl, aryl and heteroaryl can be substituted with one or more Ra;

Ra and Rb are each independently selected from H, D, halogen, CN, oxo (=O), OH, NH₂, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₁₋₆ alkylamino, C₂₋₄ alkyenyl, C₁₋₄ haloalkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkynyl, C₃₋₆ saturated or partially unsaturated carbocyclyl, C₃₋₆ halogenated saturated or partially unsaturated carbocyclyl, C₃₋₆ saturated or partially unsaturated carbocyclyl-O-, 4-12 membered heterocyclyl;

wherein, the heterocyclyl is a saturated or partially unsaturated non-aromatic group; the carbocyclyl or heterocyclyl can be optionally in the form of a monocycle, bridged ring, spirocycle, or fused ring.


2. The compound according to claim 1, or a tautomer, a stereoisomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein, the compound has a structure as shown in formula (I-1):



wherein, R₁, R₂, R₃, R₄, R₅, R₇, R₈, Cy^B and Cy^C are as defined in claim 1;

or R₇, R₄, and atoms to which they connected together form a 5-12 membered carbocyclyl or heterocyclyl.

3. The compound according to claim 1, or a tautomer, a stereoisomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein, the compound has a structure as shown in formula (I-2):



4. The compound according to claim 1, or a tautomer, a stereoisomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein, R₈ is selected from the group consisting of H, NH₂, C₁₋₆ alkyl, and C₁₋₆ alkylamino.

5. The compound according to claim 1, or a tautomer, a stereoisomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein, R_9 is selected from the group consisting of: H, D, halogen, CN, C_{1-6} alkyl and C_{1-6} haloalkyl.


6. The compound according to claim 1, or a tautomer, a stereoisomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein, Cy^B is selected from the group consisting of: phenyl and 5-7 membered heteroaryl;


preferably, Cy^B is selected from the group consisting of: phenyl, pyridyl, pyrimidinyl, pyridazinyl, pyrrolyl, furanyl, thienyl, imidazolyl, pyrazolyl, thiazolyl, triazolyl, and oxazolyl.

7. The compound according to claim 1, or a tautomer, a stereoisomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein, Cy^C is selected from the group consisting of: phenyl, 5-7 membered heteroaryl, saturated or partially unsaturated C_{3-6} saturated or partially unsaturated carbocyclyl, and saturated or partially unsaturated 4-7 membered heterocyclyl;

preferably, Cy^C is selected from the group consisting of: phenyl, pyridyl, pyrimidinyl, pyridazinyl, pyrrolyl, furanyl, thiophenyl, imidazolyl, pyrazolyl, thiazolyl, triazolyl, oxazolyl, and 5-7 membered saturated or partially unsaturated heterocyclyl.

8. The compound according to claim 1, or a tautomer, a stereoisomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein, R_5 is $-L-R_w$, wherein L is selected from the group consisting of: covalent bonds, $-C_{1-4}$ alkyl, and $-NR_6-$; R_6 is selected from the group consisting of: H, and C_{1-6} alkyl;
















R_w is selected from the group consisting of: cyano, ,






membered nitrogen-containing heterocyclyl;
















R^{WA} , R^{WB} , and R^{WC} are each independently selected from the group consisting of: H, D, halogen, C_{1-6} alkyl, and C_{1-6} haloalkyl; and R^{WA} , R^{WB} , and R^{WC} can each be independently substituted with 1, 2, or 3 substituents selected from the group consisting of: C_{1-6} alkylamino and C_{1-6} alkoxy;
















or R_6 and R_w together form a ring; and the ring is selected from the group consisting of: 5-7 membered heteroaryl and 4-7 membered heterocyclyl.






5


























5




































5

































5














5 .

11. A pharmaceutical composition, comprising:

(1) one or more of the compound according to claim 1, or a tautomer, a stereoisomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof;

10 (2) one or more pharmaceutically acceptable carriers, excipients, adjuvants, excipients, and/or diluents.

12. The pharmaceutical composition according to claim 11 for use in the treating or preventing diseases or condition associated with abnormal activity or expression levels of FGFR;

15 preferably, the disease or condition is selected from the group consisting of:

cholangiocarcinoma, hepatic carcinoma, breast carcinoma, prostate carcinoma, lung carcinoma,

thyroid carcinoma, gastric carcinoma, ovarian carcinoma, rectal carcinoma, endometrial carcinoma and uroepithelial carcinoma;

more preferably, the cholangiocarcinoma is intrahepatic cholangiocarcinoma;

further more preferably, the hepatic carcinoma is hepatocellular carcinoma;

5 the most preferably, the lung carcinoma is squamous cell carcinoma or non-small cell lung carcinoma.

13. Use of the compound according to claim 1, or a tautomer, a stereoisomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or mixtures thereof in the preparation a
10 pharmaceutical composition for treating or preventing diseases or conditions associated with abnormal activity or expression levels of FGFR;

preferably, the disease or condition is specifically associated with a subtype of FGFR;

more preferably, the FGFR subtype is selected from the group consisting of: FGFR2.